Marseille E

Collaboration for the Economics of Psychedelics, University of California Berkeley, Berkeley, CA, USA. emarseille1@berkeley.edu.

8 papers

ArticlePsychedelics

Well-being as a primary endpoint in clinical trials: a call for consensus.

Marseille E, Kettner H, Sgambati TJ +6

Europe PMC2026
ArticlePsilocybin

Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico.

Leeman L, Armstrong M, Menashi D +5

Europe PMC2026
ArticlePsilocybin

Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.

Abramsky-Sze S, Marseille E, Matzopoulos R +2

Europe PMC2026
ArticlePsilocybin

Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence.

Shiju S, Tirumala R, Marseille E

Europe PMC2026
ArticlePsilocybin

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis.

Avanceña ALV, Vuong L, Kahn JG +1

Europe PMC2025
ArticlePsilocybin

Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.

Abramsky-Sze S, Marseille E, Matzopoulos R +2

Europe PMC2025
ArticlePsilocybin

Group psychedelic therapy: empirical estimates of cost-savings and improved access.

Marseille E, Stauffer CS, Agrawal M +5

Europe PMC2023
ArticlePsilocybin

The economics of psychedelic-assisted therapies: A research agenda.

Marseille E, Bertozzi S, Kahn JG

Europe PMC2022